Elliott Investment Management's Marc Steinberg at #JPM24 (Brian Benton Photography)

January 8, 2024 03:48 PM EST

Elliott's Marc Steinberg sees more healthcare investments for the sometimes-activist firm this year: #JPM24

Drew Armstrong

Executive Editor

Andrew Dunn

Senior Biopharma Correspondent

SAN FRANCISCO — After 2023’s set of high-profile activist investments in healthcare, Elliott Investment Management’s Marc Steinberg sees more action this year in the space for …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Elliott's Marc Steinberg sees more healthcare investments for the sometimes-activist firm this year: #JPM24

Drew Armstrong

Executive Editor

Andrew Dunn

Senior Biopharma Correspondent

Sign up to read this article for free.

Among pharma CEOs, the IRA now and the IRA later get very different reactions

Bristol Myers restarts radiopharmaceutical Phase 3 trial, but delays readout by one year

Updated: With cost-cutting underway, Bristol Myers raises guidance, touts Phase 3 win and scraps another

Andrew Left, short seller who campaigned against Valeant, is accused of fraud by SEC

European drug regulator rejects Alzheimer's drug Leqembi, citing safety concerns

Critical Junctures in Gene Therapy Clinical Material Manufacturing: Where Do I Start? And Will It Work?

El­liot­t's Marc Stein­berg sees more health­care in­vest­ments for the some­times-ac­tivist firm this year: #JPM24

Executive Editor

Senior Biopharma Correspondent

Sign up to read this article for free.

Elliott's Marc Steinberg sees more healthcare investments for the sometimes-activist firm this year: #JPM24